Health Catalyst, Inc. (NASDAQ:HCAT) Shares Sold by Janney Montgomery Scott LLC

Janney Montgomery Scott LLC cut its position in shares of Health Catalyst, Inc. (NASDAQ:HCAT) by 55.1% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 49,496 shares of the company’s stock after selling 60,744 shares during the period. Janney Montgomery Scott LLC’s holdings in Health Catalyst were worth $350,000 at the end of the most recent quarter.

Other institutional investors have also made changes to their positions in the company. Quest Partners LLC purchased a new stake in shares of Health Catalyst during the third quarter worth approximately $34,000. nVerses Capital LLC purchased a new position in Health Catalyst in the third quarter worth $59,000. Quadrature Capital Ltd purchased a new position in Health Catalyst in the 3rd quarter valued at approximately $84,000. Harbor Capital Advisors Inc. grew its stake in Health Catalyst by 21.3% in the 3rd quarter. Harbor Capital Advisors Inc. now owns 11,764 shares of the company’s stock valued at $96,000 after acquiring an additional 2,064 shares during the last quarter. Finally, Intech Investment Management LLC purchased a new stake in Health Catalyst during the 3rd quarter worth about $145,000. 85.00% of the stock is currently owned by institutional investors and hedge funds.

Health Catalyst Price Performance

Shares of NASDAQ:HCAT opened at $5.75 on Tuesday. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.41 and a quick ratio of 1.41. The stock has a market capitalization of $349.89 million, a P/E ratio of -4.26 and a beta of 1.34. The business has a 50-day moving average of $6.80 and a two-hundred day moving average of $7.41. Health Catalyst, Inc. has a fifty-two week low of $5.32 and a fifty-two week high of $10.31.

Insider Buying and Selling

In other news, CFO Jason Alger sold 19,599 shares of the company’s stock in a transaction that occurred on Friday, December 6th. The stock was sold at an average price of $8.32, for a total transaction of $163,063.68. Following the completion of the transaction, the chief financial officer now directly owns 86,712 shares in the company, valued at $721,443.84. The trade was a 18.44 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Daniel Lesueur sold 5,209 shares of the stock in a transaction on Wednesday, February 5th. The shares were sold at an average price of $5.76, for a total transaction of $30,003.84. Following the completion of the sale, the chief operating officer now directly owns 86,044 shares of the company’s stock, valued at approximately $495,613.44. This trade represents a 5.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 81,169 shares of company stock worth $629,068. 2.50% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several equities analysts recently commented on the stock. Wells Fargo & Company dropped their price target on shares of Health Catalyst from $13.00 to $10.00 and set an “overweight” rating for the company in a research report on Tuesday, January 21st. Piper Sandler reiterated an “overweight” rating and issued a $12.00 target price (up previously from $11.00) on shares of Health Catalyst in a research report on Tuesday, November 26th. KeyCorp raised Health Catalyst from a “sector weight” rating to an “overweight” rating and set a $9.00 target price on the stock in a research report on Wednesday, January 8th. Royal Bank of Canada decreased their target price on shares of Health Catalyst from $9.00 to $7.00 and set a “sector perform” rating for the company in a research report on Wednesday, January 15th. Finally, Citigroup dropped their price target on Health Catalyst from $10.50 to $10.00 and set a “buy” rating on the stock in a report on Friday, January 10th. Two investment analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat.com, Health Catalyst presently has an average rating of “Moderate Buy” and an average price target of $10.60.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.